Pharmacokinetic drug interaction profile of omeprazole with adverse consequences and clinical risk management

Therapeutics and Clinical Risk Management

Volumn 9, Issue 1, 2013, Pages 259-271

  Zhou, Quan ^a   Li, Wei ^a   Zeng, Su ^b   Yu, Lu Shan ^b  

^a ZHEJIANG UNIVERSITY   (China)

^b ZHEJIANG UNIVERSITY   (China)

Author keywords

Administration schedule; Drug interactions; Drug toxicity; Herb drug interactions; Omeprazole; Pharmacokinetics; Polypharmacy; Prescription auditing; Risk management; Treat ment failure

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIFUNGAL AGENT; ATAZANAVIR; BREAST CANCER RESISTANCE PROTEIN; CARBAMAZEPINE; CLOPIDOGREL; CLOZAPINE; CYTOCHROME P450 1A2; CYTOCHROME P450 2C19; CYTOCHROME P450 3A4; DIAZEPAM; DIGOXIN; EFAVIRENZ; GINKGO BILOBA EXTRACT; HERBACEOUS AGENT; HYPERICUM PERFORATUM EXTRACT; INDINAVIR; IRON; ITRACONAZOLE; METHOTREXATE; MULTIDRUG RESISTANCE PROTEIN; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NELFINAVIR; NORDAZEPAM; OMEPRAZOLE; POSACONAZOLE; RILPIVIRINE; TACROLIMUS; UNINDEXED DRUG;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ACUTE CORONARY SYNDROME; AREA UNDER THE CURVE; ARTEMISIA; ARTEMISIA CAPILLARIS; ATAXIA; AUTOIMMUNE DISEASE; CONFUSION; DEPRESSION; DIGITALIS INTOXICATION; DOSE RESPONSE; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MEGADOSE; DRUG TRANSPORT; DUODENUM ULCER; DYSPEPSIA; ETHNICITY; GASTROESOPHAGEAL REFLUX; GENOTYPE; HEART FAILURE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; INSOMNIA; IRON DEFICIENCY; MUSCLE SPASM; MYCOSIS; NEOPLASM; PANIC; PEPTIC ULCER; POLYPHARMACY; REVIEW; RISK ASSESSMENT; SEIZURE; SMOKING; SYSTEMIC MYCOSIS;

EID: 84881585273     PISSN: 11766336     EISSN: 1178203X     Source Type: Journal    
DOI: 10.2147/TCRM.S43151     Document Type: Review

References (91)

1. Corsonello A, Pedone C, Corica F, Incalzi RA. Polypharmacy in elderly patients at discharge from the acute care hospital. Ther Clin Risk Manag. 2007;3(1):197-203.
2. Koh Y, Kutty FB, Li SC. Drug-related problems in hospitalized patients on polypharmacy: the influence of age and gender. Ther Clin Risk Manag. 2005;1(1):39-48.
3. Doan J, Zakrzewski-Jakubiak H, Roy J, Turgeon J, Tannenbaum C. Prevalence and risk of potential cytochrome P450-mediated drug-drug interactions in older hospitalized patients with polypharmacy. Ann Pharmacother. 2013;47(3):324-332.
4. Joint Commission International. JCI accreditation standards for hos-pitals [webpage on the Internet]. Oak Brook, IL: Joint Commission International; 2010. Available from: http://www.jointcommissionin-ternational.org/common/pdfs/jcia/IAS400_Standards_Lists_Only.pdf. Accessed March 20, 2013.
5. Mahmood M, Malone DC, Skrepnek GH, et al. Potential drug-drug interactions within Veterans Affairs medical centers. Am J Health Syst Pharm. 2007;64(14):1500-1505.
6. Ogawa R, Echizen H. Drug-drug interaction profiles of proton pump inhibitors. Clin Pharmacokinet. 2010;49(8):509-533.
7. Blume H, Donath F, Warnke A, Schug BS. Pharmacokinetic drug interac-tion profiles of proton pump inhibitors. Drug Saf. 2006;29(9):769-784.
8. Gerson LB, Triadafilopoulos G. Proton pump inhibitors and their drug interactions: an evidence-based approach. Eur J Gastroenterol Hepatol. 2001;13(5):611-616.
9. Gugler R, Jensen JC. Omeprazole inhibits oxidative drug metabolism. Studies with diazepam and phenytoin in vivo and 7-ethoxycoumarin in vitro. Gastroenterology. 1985;89(6):1235-1241.
10. Zvyaga T, Chang SY, Chen C, et al. Evaluation of six proton pump inhibitors as inhibitors of various human cytochromes P450: focus on cytochrome P4502C19. Drug Metab Dispos. 2012;40(9):1698-1711.
11. Caraco Y, Tateishi T, Wood AJ. Interethnic difference in omepra-zole's inhibition of diazepam metabolism. Clin Pharmacol Ther. 1995;58(1):62-72.
12. Gugler R, Hartmann M, Rudi J, et al. Lack of pharmacokinetic interaction of pantoprazole with diazepam in man. Br J Clin Pharmacol. 1996;42(2):249-252.
13. Lefebvre RA, Flouvat B, Karolac-Tamisier S, Moerman E, Van Ganse E. Influence of lansoprazole treatment on diazepam plasma concentrations. Clin Pharmacol Ther. 1992;52(5):458-463.
14. Ishizaki T, Chiba K, Manabe K, et al. Comparison of the interaction potential of a new proton pump inhibitor, E3810, versus omeprazole with diazepam in extensive and poor metabolizers of S-mephenytoin 4′-hydroxylation. Clin Pharmacol Ther. 1995;58(2):155-164.
15. Naidu MUR, Shobha JC, Dixit VK, et al. Effect of multiple dose omeprazole on the pharmacokinetics of carbamazepine. Drug Invest. 1994;7(1):8-12.
16. Dixit RK, Chawla AB, Kumar N, Garg SK. Effect of omeprazole on the pharmacokinetics of sustained-release carbamazepine in healthy male volunteers. Methods Find Exp Clin Pharmacol. 2001;23(1):37-39.
17. Bertilsson L, Tybring G, Widén J, Chang M, Tomson T. Carbamazepine treatment induces the CYP3A4 catalysed sulphoxidation of omeprazole, but has no or less effect on hydroxylation via CYP2C19. Br J Clin Pharmacol. 1997;44(2):186-189.
18. Huber R, Bliesath H, Hartmann M, et al. Pantoprazole does not interact with the pharmacokinetics of carbamazepine. Int J Clin Pharmacol Ther. 1998;36(10):521-524.
19. Dalton MJ, Powell JR, Messenheimer JA Jr. Ranitidine does not alter single-dose carbamazepine pharmacokinetics in healthy adults. Drug Intell Clin Pharm. 1985;19(12):941-944.
20. Han XM, Ouyang DS, Chen XP, et al. Inducibility of CYP1A2 by omeprazole in vivo related to the genetic polymorphism of CYP1A2. Br J Clin Pharmacol. 2002;54(5):540-543.
21. Rost KL, Brösicke H, Heinemeyer G, Roots I. Specific and dose-dependent enzyme induction by omeprazole in human beings. Hepatology. 1994;20(5):1204-1212.
22. Frick A, Kopitz J, Bergemann N. Omeprazole reduces clozapine plasma concentrations. A case report. Pharmacopsychiatry. 2003; 36(3):121.
23. Mookhoek EJ, Loonen AJ. Retrospective evaluation of the effect of omeprazole on clozapine metabolism. Pharm World Sci. 2004;26(3): 180-182.
24. Hartmann M, Zech K, Bliesath H, et al. Pantoprazole lacks induction of CYP1A2 activity in man. Int J Clin Pharmacol Ther. 1999;37(4): 159-164.
25. Bondolfi G, Morel F, Crettol S, Rachid F, Baumann P, Eap CB. Increased clozapine plasma concentrations and side effects induced by smoking cessation in 2 CYP1A2 genotyped patients. Ther Drug Monit. 2005;27(4):539-543.
26. Falcon RW, Kakuda TN. Drug interactions between HIV pro-tease inhibitors and acid-reducing agents. Clin Pharmacokinet. 2008;47(2):75-89.
27. Burger DM, Hugen PW, Kroon FP, et al. Pharmacokinetic interaction between the proton pump inhibitor omeprazole and the HIV protease inhibitor indinavir. AIDS. 1998;12(15):2080-2082.
28. Fang AF, Damle BD, LaBadie RR, Crownover PH, Hewlett D Jr, Glue PW. Significant decrease in nelfinavir systemic exposure after omeprazole coad-ministration in healthy subjects. Pharmacotherapy. 2008;28(1):42-50.
29. Zhu L, Persson A, Mahnke L, et al. Effect of low-dose omeprazole (20 mg daily) on the pharmacokinetics of multiple-dose atazanavir with ritonavir in healthy subjects. J Clin Pharmacol. 2011;51(3):368-377.
30. Sharma M, Saravolatz LD. Rilpivirine: a new non-nucleoside reverse tran-scriptase inhibitor. J Antimicrob Chemother. 2013;68(2):250-256.
31. Tappouni HL, Rublein JC, Donovan BJ, et al. Effect of omepra-zole on the plasma concentrations of indinavir when administered alone and in combination with ritonavir. Am J Health Syst Pharm. 2008;65(5):422-428.
32. Saah AJ, Winchell GA, Nessly ML, Seniuk MA, Rhodes RR, Deutsch PJ. Pharmacokinetic profile and tolerability of indinavir-ritona-vir combinations in healthy volunteers. Antimicrob Agents Chemother. 2001;45(10):2710-2715.
33. Zhou S, Chan E, Li X, Huang M. Clinical outcomes and management of mechanism-based inhibition of cytochrome P4503A4. Ther Clin Risk Manag. 2005;1(1):3-13.
34. Boffito M, Carriero P, Trentini L, et al. Pharmacokinetics of saqui-navir co-administered with cimetidine. J Antimicrob Chemother. 2002;50(6):1081-1084.
35. Saberi P, Ranatunga DK, Quesenberry CP, Silverberg MJ. Clinical implications of the nelfinavir-proton pump inhibitor drug interaction in patients with human immunodeficiency virus. Pharmacotherapy. 2011;31(3):253-261.
36. Luber AD, Brower R, Kim D, Silverman R, Peloquin CA, Frank I. Steady-state pharmacokinetics of once-daily fosamprenavir/ritonavir and atazanavir/ritonavir alone and in combination with 20 mg omepra-zole in healthy volunteers. HIV Med. 2007;8(7):457-464.
37. Van Heeswijk R, Hoetelmans R, Kestens D, et al; for: International AIDS Society; The pharmacokinetic (PK) interaction between famo-tidine and TMC278, a next generation non-nucleoside reverse tran-scriptase inhibitor (NNRTI), in HIV-negative volunteers. Proceedings of the Fourth IAS Conference on HIV Pathogenesis, Treatment, and Prevention; 2007; Sydney, Australia.
38. Brown KC, Paul S, Kashuba AD. Drug interactions with new and investigational antiretrovirals. Clin Pharmacokinet. 2009;48(4): 211-241.
39. Beorlegui B, Aldaz A, Ortega A, Aquerreta I, Sierrasesúmega L, Giráldez J. Potential interaction between methotrexate and omeprazole. Ann Pharmacother. 2000;34(9):1024-1027.
40. Bezabeh S, Mackey AC, Kluetz P, Jappar D, Korvick J. Accumulating evidence for a drug-drug interaction between methotrexate and proton pump inhibitors. Oncologist. 2012;17(4):550-554.
41. Bauters TG, Verlooy J, Robays H, Laureys G. Interaction between methotrexate and omeprazole in an adolescent with leukemia: a case report. Pharm World Sci. 2008;30(4):316-318.
42. Ranchon F, Vantard N, Gouraud A, et al. Suspicion of drug-drug interaction between high-dose methotrexate and proton pump inhibi-tors: a case report-should the practice be changed? Chemotherapy. 2011;57(3):225-229.
43. Christians U, Schmidt G, Bader A, et al. Identification of drugs inhibit-ing the in vitro metabolism of tacrolimus by human liver microsomes. Br J Clin Pharmacol. 1996;41(3):187-190.
44. Maguire M, Franz T, Hains DS. A clinically significant interaction between tacrolimus and multiple proton pump inhibitors in a kidney transplant recipient. Pediatr Transplant. 2012;16(6):E217-E220.
45. Hosohata K, Masuda S, Katsura T, et al. Impact of intestinal CYP2C19 genotypes on the interaction between tacrolimus and omepra-zole, but not lansoprazole, in adult living-donor liver transplant patients. Drug Metab Dispos. 2009;37(4):821-826.
46. Hosohata K, Masuda S, Ogura Y, et al. Interaction between tacrolimus and lansoprazole, but not rabeprazole in living-donor liver transplant patients with defects of CYP2C19 and CYP3A5. Drug Metab Pharmacokinet. 2008;23(2):134-138.
47. Hosohata K, Masuda S, Yonezawa A, et al. Absence of influence of concomitant administration of rabeprazole on the pharmacokinetics of tacrolimus in adult living-donor liver transplant patients: a case-control study. Drug Metab Pharmacokinet. 2009;24(5):458-463.
48. Takahashi K, Yano I, Fukuhara Y, et al. Distinct effects of omeprazole and rabeprazole on the tacrolimus blood concentration in a kidney trans-plant recipient. Drug Metab Pharmacokinet. 2007;22(6):441-444.
49. Lorf T, Ramadori G, Ringe B, Schwörer H. The effect of pantoprazole on tacrolimus and cyclosporin A blood concentration in transplant recipients. Eur J Clin Pharmacol. 2000;56(5):439-440.
50. Doesch AO, Mueller S, Konstandin M, et al. Proton pump inhibi-tor co-medication reduces active drug exposure in heart transplant recipients receiving mycophenolate mofetil. Transplant Proc. 2010; 42(10):4243-4246.
51. David-Neto E, Takaki KM, Agena F, et al. Diminished mycophenolic acid exposure caused by omeprazole may be clinically relevant in the first week posttransplantation. Ther Drug Monit. 2012;34(3):331-336.
52. Kiberd BA, Wrobel M, Dandavino R, Keown P, Gourishankar S. The role of proton pump inhibitors on early mycophenolic acid exposure in kidney transplantation: evidence from the CLEAR study. Ther Drug Monit. 2011;33(1):120-123.
53. Kees MG, Steinke T, Moritz S, et al. Omeprazole impairs the absorption of mycophenolate mofetil but not of enteric-coated mycophenolate sodium in healthy volunteers. J Clin Pharmacol. 2012;52(8):1265-1272.
54. Drepper MD, Spahr L, Frossard JL. Clopidogrel and proton pump inhibitors - where do we stand in 2012? World J Gastroenterol. 2012;18(18):2161-2171.
55. Norgard NB, Mathews KD, Wall GC. Drug-drug interaction between clopidogrel and the proton pump inhibitors. Ann Pharmacother. 2009;43(7):1266-1274.
56. Bhatt DL, Cryer BL, Contant CF, et al; for COGENT Investigators. Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med. 2010;363(20):1909-1917.
57. Bates ER, Lau WC, Angiolillo DJ. Clopidogrel-drug interactions. J Am Coll Cardiol. 2011;57(11):1251-1263.
58. Wu J, Jia LT, Shao LM, et al. Drug-drug interaction of rabeprazole and clopidogrel in healthy Chinese volunteers. Eur J Clin Pharmacol. 2013;69(2):179-187.
59. Neubauer H, Engelhardt A, Krüger JC, et al. Pantoprazole does not influence the antiplatelet effect of clopidogrel-a whole blood aggregometry study after coronary stenting. J Cardiovasc Pharmacol. 2010;56(1):91-97.
60. Frelinger AL 3rd, Lee RD, Mulford DJ, et al. A randomized, 2-period, crossover design study to assess the effects of dexlansoprazole, lanso-prazole, esomeprazole, and omeprazole on the steady-state pharma-cokinetics and pharmacodynamics of clopidogrel in healthy volunteers. J Am Coll Cardiol. 2012;59(14):1304-1311.
61. Tunggal P, Ng FH, Lam KF, Chan FK, Lau YK. Effect of esomeprazole versus famotidine on platelet inhibition by clopidogrel: a double-blind, randomized trial. Am Heart J. 2011;162(5):870-874.
62. Ng FH, Tunggal P, Chu WM, et al. Esomeprazole compared with famotidine in the prevention of upper gastrointestinal bleeding in patients with acute coronary syndrome or myocardial infarction. Am J Gastroenterol. 2012;107(3):389-396.
63. Gurbel PA, Bliden KP, Fort JG, et al. Spaced administration of PA32540 and clopidogrel results in greater platelet inhibition than synchronous administration of enteric-coated aspirin and enteric-coated omeprazole and clopidogrel. Am Heart J. 2013;165(2):176-182.
64. Kiley CA, Cragin DJ, Roth BJ. Omeprazole-associated digoxin toxicity. South Med J. 2007;100(4):400-402.
65. Gabello M, Valenzano MC, Barr M, Zurbach P, Mullin JM. Omeprazole induces gastric permeability to digoxin. Dig Dis Sci. 2010; 55(5):1255-1263.
66. Collett A, Tanianis-Hughes J, Carlson GL, Harwood MD, Warhurst G. Comparison of P-glycoprotein-mediated drug-digoxin interactions in Caco-2 with human and rodent intestine: relevance to in vivo prediction. Eur J Pharm Sci. 2005;26(5):386-393.
67. Pauli-Magnus C, Rekersbrink S, Klotz U, Fromm MF. Interaction of omeprazole, lansoprazole and pantoprazole with P-glycoprotein. Naunyn Schmiedebergs Arch Pharmacol. 2001;364(6):551-557.
68. Hartmann M, Huber R, Bliesath H, et al. Lack of interaction between pantoprazole and digoxin at therapeutic doses in man. Int J Clin Pharmacol Ther. 1996;34(Suppl 1):S67-S71.
69. Jaruratanasirikul S, Sriwiriyajan S. Effect of omeprazole on the pharma-cokinetics of itraconazole. Eur J Clin Pharmacol. 1998;54(2):159-161.
70. Johnson MD, Hamilton CD, Drew RH, Sanders LL, Pennick GJ, Perfect JR. A randomized comparative study to determine the effect of omepra-zole on the peak serum concentration of itraconazole oral solution. J Antimicrob Chemother. 2003;51(2):453-457.
71. Alffenaar JW, van Assen S, van der Werf TS, Kosterink JG, Uges DR. Omeprazole significantly reduces posaconazole serum trough level. Clin Infect Dis. 2009;48(6):839.
72. Lange D, Pavao JH, Wu J, Klausner M. Effect of a cola beverage on the bioavailability of itraconazole in the presence of H2 blockers. J Clin Pharmacol. 1997;37(6):535-540.
73. Dolton MJ, Ray JE, Marriott D, McLachlan AJ. Posaconazole exposure-response relationship: evaluating the utility of therapeutic drug monitoring. Antimicrob Agents Chemother. 2012;56(6):2806-2813.
74. Ross AL, Slain D, Cumpston A, Bryant AM, Hamadani M, Craig M. Evaluation of an alternative posaconazole prophylaxis regimen in haematological malignancy patients receiving concomitant stress ulcer prophylaxis. Int J Antimicrob Agents. 2012;40(6):557-561.
75. Ajmera AV, Shastri GS, Gajera MJ, Judge TA. Suboptimal response to ferrous sulfate in iron-deficient patients taking omeprazole. Am J Ther. 2012;19(3):185-189.
76. Karam WG, Goldstein JA, Lasker JM, Ghanayem BI. Human CYP2C19 is a major omeprazole 5-hydroxylase, as demonstrated with recombinant cytochrome P450 enzymes. Drug Metab Dispos. 1996;24(10):1081-1087.
77. Faucette SR, Zhang TC, Moore R, et al. Relative activation of human pregnane X receptor versus constitutive androstane receptor defines distinct classes of CYP2B6 and CYP3A4 inducers. J Pharmacol Exp Ther. 2007;320(1):72-80.
78. Chen Y, Ferguson SS, Negishi M, Goldstein JA. Identification of con-stitutive androstane receptor and glucocorticoid receptor binding sites in the CYP2C19 promoter. Mol Pharmacol. 2003;64(2):316-324.
79. Mugundu GM, Hariparsad N, Desai PB. Impact of ritonavir, atazanavir and their combination on the CYP3A4 induction potential of efavirenz in primary human hepatocytes. Drug Metab Lett. 2010;4(1):45-50.
80. Michaud V, Ogburn E, Thong N, et al. Induction of CYP2C19 and CYP3A activity following repeated administration of efavirenz in healthy volunteers. Clin Pharmacol Ther. 2012;91(3):475-482.
81. Wang LS, Zhou G, Zhu B, et al. St John's Wort induces both cytochrome P4503A4-catalyzed sulfoxidation and 2C19-dependent hydroxylation of omeprazole. Clin Pharmacol Ther. 2004;75(3):191-197.
82. Xie HG. Additional discussions regarding the altered metabolism and transport of omeprazole after long-term use of St John's Wort. Clin Pharmacol Ther. 2005;78(4):440-441.
83. Zuo XC, Zhang BK, Jia SJ, et al. Effects of Ginkgo biloba extracts on diazepam metabolism: a pharmacokinetic study in healthy Chinese male subjects. Eur J Clin Pharmacol. 2010;66(5):503-509.
84. Lei HP, Wang G, Wang LS, et al. Lack of effect of Ginkgo biloba on voriconazole pharmacokinetics in Chinese volunteers identified as CYP2C19 poor and extensive metabolizers. Ann Pharmacother. 2009;43(4):726-731.
85. Zadoyan G, Rokitta D, Klement S, et al. Effect of Ginkgo biloba spe-cial extract EGb761® on human cytochrome P450 activity: a cocktail interaction study in healthy volunteers. Eur J Clin Pharmacol. 2012; 68(5):553-560.
86. Yin OQ, Tomlinson B, Waye MM, Chow AH, Chow MS. Pharmacogenetics and herb-drug interactions: experience with Ginkgo biloba and omeprazole. Pharmacogenetics. 2004;14(12): 841-850.
87. Huang W, Zhang J, Moore DD. A traditional herbal medicine enhances bilirubin clearance by activating the nuclear receptor CAR. J Clin Invest. 2004;113(1):137-143.
88. Fan L, Wang G, Wang LS, et al. Herbal medicine yin zhi huang induces CYP3A4-mediated sulfoxidation and CYP2C19-dependent hydroxylation of omeprazole. Acta Pharmacol Sin. 2007;28(10): 1685-1692.
89. Pace F, Pallotta S, Casalini S, Porro GB. A review of rabeprazole in the treatment of acid-related diseases. Ther Clin Risk Manag. 2007; 3(3):363-379.
90. Marelli S, Pace F. Rabeprazole for the treatment of acid-related disorders. Expert Rev Gastroenterol Hepatol. 2012;6(4):423-435.
91. Moher D, Liberati A, Tetzlaff J, Altman DG; for PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339:b2535.